Fulcrum Occupancy–Leverage Perturbation Strategy Enables Rapid Discovery of Potent CDK2–Cyclin A2 Interaction Inhibitors
Abstract
AbstractTraditional strategies for developing small‐molecule inhibitors of protein–protein interactions (PPIs) are time‐consuming and often yield low success rates due to the flat and dynamic interfaces of PPIs. To enable the rapid design of highly potent PPI inhibitors, we proposed a novel strategy named “Fulcrum Occupancy–Leverage Perturbation (FOLP)”. In this strategy, high‐affinity fragments serve as the “Fulcrum” by binding to the orthosteric pocket, while suitable moieties extend into allosteric sites near the PPI interface as “Leverage” to modulate the protein–protein interaction. As a proof of concept, the potent CDK2–Cyclin A2 PPI inhibitor LC‐K2CAin‐3, which fits the “FOLP” paradigm, was discovered with an IC50 of 32.1 nM for inhibiting the interaction. Molecular dynamics simulations and cryptic pocket identification were employed, revealing the activation loop (A‐loop) of CDK2 was flexible and targetable. X‐ray crystallography and hydrogen deuterium exchange mass spectrometry (HDX‐MS) analysis showed that LC‐K2CAin‐3 indeed bound to and stabilized the A‐loop. LC‐K2CAin‐3 effectively inhibited the CDK2–Cyclin A2 interaction in CDK2 highly expressed melanoma cells, leading to cell cycle arrest and apoptosis and inhibition of CDK2 mediated signaling. In conclusion, the “FOLP” strategy offers a novel approach for PPI inhibitor discovery and could accelerate the development of PPI inhibitors.
Article Details
Authors (22)
Ge Sun
Pritzker School of Molecular Engineering
Shuaishuai Chi
State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 P.R. China
Jiacheng Li
Department of Medicine, The University of Chicago, Chicago, IL, USA.
Pan Xu
Tingting Lin
Chao Chen
Liping Liu
Yulin Yang
Ruyu Yan
State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 P.R. China
Hongbo Han
Mingyu Wang
Shuiping Fu
State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 P.R. China
Junyi Qiu
Mingchen Wang
Fan Wei
Yaxi Yang
State Key Laboratory of Drug Research Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai 201203 P.R. China
Jie Zheng
Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology
Kaixian Chen
State Key Laboratory of Drug Research
Shijie Chen
Innovation Center for AI and Drug Discovery, School of Pharmacy
Yi Chen
Bing Zhou
Cheng Luo
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine